Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

Glaucoma Clinical Trial

Official title:

A Randomized, Open-label, 2-period, Parallel Group, Multiple-dose Phase 1 Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930, in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05207761
• Other study ID #: A71_05DDI2114
• Status: Completed
• Phase: Phase 1
• Start date: January 19, 2022
• Est. completion date: November 2, 2022

Study information

• Verified date: January 2023
• Source: Chong Kun Dang Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects

Description:

To healthy male subjects of thirty-two (32), Investigational products are administered following treatments in each period

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: November 2, 2022
• Est. primary completion date: October 18, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 19 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy adults volunteers aged between 19 and 55 years old at the time of screening

2. Weight = 55 kg, Calculated Body Mass Index(BMI) of 18.0 to 30.0 kg/m2

• BMI = Weight(kg)/ Height(m)2

3. Individuals who sign an informed consent form and decide to participate in the study after being fully informed of the study prior to participation

4. Individuals who are suitable as a subject for this study at the discretion of the researcher as a result of screening tests such as examination, laboratory tests and questionnaires

Exclusion Criteria:

1. Individuals who have other clinically significant cardiovascular system, respiratory system, liver, renal, nervous system, endocrine system, blood-oncology, psychiatric disorders, urinary system or ophthalmic diseases or have a history

2. Individuals who satisfy the following items during the interview or examination

• Individuals with a history of or sign or symptoms of a disease of the visual system

• Individuals who had an ophthalmic surgery including for refractive correction surgery such as LASIK.

• Individuals with corrected visual acuity of 20/40 or less

• Individuals who have experienced side effects after wearing contact lenses or who have worn contact lenses within the last month

• Individuals who have more than 21mmHg or less than 10mmHg on either side of the intraocular pressure test

• Individuals who show abnormal findings in other ophthalmic examinations

3. Individuals who have a history of hypersensitivity to the active ingredient and component of the investigational drug, or to the drug in the same class as the active ingredient

4. Individuals with sitting systolic blood pressure = 140 mmHg or = 80 mmHg or sitting diastolic blood pressure = 90 mmHg or = 45 mmHg

5. Individuals with the following results at screening test

• AST, ALT, ?-GT > 2x the upper limit of the normal range

• Total bilirubin > 2.0 mg/dL

• eGFR(CKD-EPI) < 60 mL/min/1.73m2

6. Individuals who continue to drink(over 21 units/week) within 1 month or cannot abstain from alcohol during the clinical trial period

7. Individuals who tested positive in an alcohol breath analysis

8. Individuals who continuously smoke within one month(including e-cigarettes, over 10 fees/day) or who cannot quit smoking during the clinical trial period;

9. Individuals who cannot restrict the intake of grapefruit or grapefruit-containing food from 3 days before administration of investigational drugs to the final pharmacokinetic blood sample collection

10. Individuals who tested positive for urine cotinine at screening test

11. Individuals who took ethical(ETC) or oriental medicine within 2 weeks or over the counter(OTC) within 1 week before the expected first dose

12. Individuals taking medication known to significantly induce or inhibit drug metabolizing enzymes within 1 month before the expected first dose

13. Individuals with a medical history of significant drug abuse or positive for abuse drug in urine test results at screening

14. Individuals who had been administered investigational product(s) of other clinical study within the 6 months prior to the first dose of this study

15. Individuals who donated whole blood within the 2 months, or donated blood components within 1 month, or received a blood transfusion with 1month prior to the first dose or plan to donate blood or transfusion during the clinical trial period

16. Individuals who are unable to use an appropriate medically approved method of contraception for themselves, their spouses, or partners during the entire clinical trial period and for at least 90 days after the last investigational drug administration and cannot donate sperm during this period

17. Individuals who were deemed to be inappropriate to participate in the study by the investigator

Related Conditions & MeSH terms

• Glaucoma

Intervention

Drug:
• D565
Q.D. in both eye
• D930
T.I.D in both eye

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University College of Medicine and Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUCtau,ss of D565(Sequence1)	Area under the D565 concentration in blood-time curve from 0 to t at steady state	1day 0hour ~ 99day 0hour
Primary	AUCtau,ss of D930(Sequence1)	Area under the D930 concentration in blood-time curve from 0 to t at steady	8day 0hour ~ 99day 0hour
Primary	AUCtau,ss of D565(Sequence2)	Area under the D565 concentration in blood-time curve from 0 to t at steady state	96day 0hour ~ 99day 0hour
Primary	AUCtau,ss of D930(Sequence2)	Area under the D930 concentration in blood-time curve from 0 to t at steady	1day 0hour ~ 99day 0hour
Primary	Cmax,ss of D565(Sequence1)	The maximum D565 concentration between 0 and t at steady state	1day 0hour ~ 99day 0hour
Primary	Cmax,ss of D930(Sequence1)	The maximum D930 concentration between 0 and t at steady state	8day 0hour ~ 99day 0hour
Primary	Cmax,ss of D565(Sequence2)	The maximum D565 concentration between 0 and t at steady state	96day 0hour ~ 99day 0hour
Primary	Cmax,ss of D930(Sequence2)	The maximum D930 concentration between 0 and t at steady state	1day 0hour ~ 99day 0hour